Primary Human Liver Endothelial Cells Supply

The contract seeks the supply of primary human liver sinusoidal endothelial cells for integration into 3D microphysiological systems, specifically targeting advanced in vitro modeling applications. The cells must meet stringent biological and functional standards to ensure compatibility with complex tissue platforms used in pharmacological and toxicological research. The procurement is classified as a subcontract under NAICS code 325414, indicating a focus on pharmaceutical and biological product manufacturing, and is managed by the National Institutes of Health under the Department of Health and Human Services. Performance is required to occur in a facility located in North Carolina with ZIP code 27709, though no specific city or point of contact is provided. Responses must be submitted by July 22, 2026, with the solicitation posting date listed as July 6, 2026, indicating a limited window for interested parties to prepare and submit proposals. There is no set-aside designation specified, meaning the opportunity is open to all eligible contractors without preference given to small businesses, historically underutilized firms, or other categories. The absence of detailed contact information or office location suggests the procurement is being handled through centralized federal systems, and all inquiries or submissions must be processed via the provided SAM.gov portal link. The contract is critical for advancing human-relevant models for liver-specific drug metabolism, disease studies, and predictive toxicology.